[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 1984

Topical Erythromycin v Clindamycin Therapy for AcneA Multicenter, Double-blind Comparison

Author Affiliations

From the Department of Dermatology, Downstate Medical Center, Brooklyn, NY (Dr Shalita); the Department of Dermatology, University of Texas Medical Branch, Galveston (Dr Smith); and the Division of Dermatology, Washington University School of Medicine, St Louis (Dr Bauer).

Arch Dermatol. 1984;120(3):351-355. doi:10.1001/archderm.1984.01650390073015

• The efficacy and safety of topical 1.5% erythromycin solution and 1% clindamycin phosphate solution were compared in the treatment of acne. The number of inflammatory lesions was significantly reduced at 12 weeks by 62% and 59% and the number of noninflammatory lesions by 43% and 39% in the erythromycin and clindamycin groups, respectively. The reduction in lesions was also reflected in the clinical evaluation of the overall facial condition; 73% of the 74 patients treated with erythromycin solution and 62% of the 80 patients treated with clindamycin solution had excellent or good responses at 12 weeks. The results of this study show that topically applied 1.5% erythromycin and 1.0% clindamycin solutions are both effective and comparable in reducing the clinical manifestation of acne in patients with moderate disease.

(Arch Dermatol 1984;120:351-355)